the aid library

LIST OPTIONS

Filter

5485

Sort by:

Direction:

Download (449)

View PDF (813)

Design and validation of a trachomatous trichiasis - only survey

World Health Organization (WHO), Strategic and Technical Advisory Group for Neglected Tropical Diseases, Working Group on Monitoring and Evaluation (2017) C_WHO

The World Health Organization (WHO) endorses the use of population-based prevalence surveys for estimating the prevalence of trachoma. In general, the prevalence of TF in children aged 1–9 years and the prevalence of TT in adults aged ≥ 15 years are measured at the same time in any district bein... more

Download (125)

View PDF (180)

Status Report on prison health in Europe

World Health Organization (Europe) (2019) C_WHO

Overwhelming evidence shows that a range of health concerns—mental illness, substance dependence, HIV/AIDS, and noncommunicable diseases—affect prisoners disproportionately. But, while incarceration poses risks to health—including inadequate nutrition and exposure to violence—prisons also pr... more

Download (739)

View PDF (1209)

Guidance on tuberculosis control in vulnerable and hard-to-reach populations

Andreas Sandgren, Marieke J. van der Werf, Netta Beer et al. (2016) CC

This guidance provides an overview of interventions to improve early diagnosis of TB and treatment completion in these populations, as well as factors to consider when developing programmes for health communication, awareness and education, and programme monitoring and evaluation

Download (462)

View PDF (1109)

Indonesia: Disaster Management Reference Handbook

Center for Excellence in Disaster Management and Humanitarian Assistance (2018) C1

The Indonesian government has reformed its laws, policies, and institutions to better manage disaster risk since the significant 2004 Indian Ocean Tsunami. The Government of Indonesia now has contingency plans for every disaster-prone city which identifies its vulnerabilities, outlines the relief re... more

Download (250)

View PDF (280)

Safe listening. Devices and Systems

World Health Organization WHO (2019) C_WHO

A WHO-ITU Standard. Nearly 50% of people aged 12-35 years – or 1.1 billion young people – are at risk of hearing loss due to prolonged and excessive exposure to loud sounds, including music they listen to through personal audio devices. Ahead of World Hearing Day (3 March), the World Health Org... more

Download (119)

View PDF (156)

Addressing the antibiotic resistance threat– the role of water, sanitation and hygiene

ReAct (2020) C2

Antibiotic resistant bacteria are spreading at an alarming rate and some bacterial infections may once again be untreatable. Antibiotic resistance (ABR), conservatively calculated, causes more than 500 000 deaths every year. This number is projected to rise dramatically if radical actions are not ta... more

Download (97)

View PDF (137)

Coronavirus: Healthcare and human rights of people in prison

Penal Reform International (PRI) (2020) C2

Briefing note | 16 March 2020 Do no harm, equality, transparency, humanity: values should guide the criminal justice sector’s response to coronavirus At the time of publishing there were more than 164,000* confirmed cases of COVID- 19, the novel form of Coronavirus, affecting 110 countries wit... more

Download (86)

View PDF (136)

Coronavirus in Sub-Saharan Africa - How africans in 12 nations are responding to the COVID-19 outbreak

GeoPoll (2020) C2

The spread of COVID-19 poses a challenge for emerging markets such as those in Africa and Latin America. While governments around the world are suffering from a shortage of ventilators, hospital beds, and personal protective equipment, availability of these items is already extremely limited in some... more

Download (122)

View PDF (144)

"The greatest need was to be listened to": The importance of mental health and psychosocial support during COVID-19

International Federation of Red Cross and Red Crescent Societies (IFRC) (2020) C1

Experiences and recommendations from the International Red Cross and Red Crescent Movement. Measures imposed by governments to prevent the spread of the disease, including lockdown restrictions, quarantines, physical distancing, and their economic and social consequences, further increase this dist... more

Download (144)

View PDF (186)

Children with disabilities - Ensuring their inclusion in COVID-19 response strategies and evidence generation

UN Children's Fund UNICEF (2020) CC

The publication draws on pre-COVID data to highlight how children with disabilities face greater risks in the midst of this pandemic. It documents what has happened to services for children and adults with disabilities across the world and includes examples of what has been done to address disruptio... more

Download (156)

View PDF (234)

Mapping of best community practices for accompanying eviction situations of refugees and migrants from Venezuela

R4V (2021) CC

This mapping of community experiences for the defense of the right to adequate housing in situations of risk of eviction or eviction in progress brings together practices and strategies used by families, collectives and community organizations that have different origins and interests in the region,... more

Download (91)

View PDF (139)

Health effects of particulate matter: policy implications for countries in eastern Europe, Caucasus and central Asia

World Health Organization WHO (2013) C_WHO

Despite some improvements, current levels of air pollution still pose a considerable risk to the environment and to human health in the WHO European Region. One issue of concern is that monitoring of particulate matter is very limited in the countries of eastern Europe, the Caucasus and central Asia... more

Download (117)

View PDF (142)

Global roadmap for research and development of tuberculosis vaccines

European & Developing Countries Clinical Trials Partnership EDCTTP; Amterdam Institute for Global health & Development aighd (2021) C1

The roadmap describes the actions needed to achieve the three development goals for TB vaccines set by the WHO: 1. A safe, effective and affordable TB vaccine for adolescents and adults. 2. An affordable TB vaccine for neonates and infants with improved safety and efficacy. 3. A therapeutic v... more

Download (88)

View PDF (364)

Nature-Based Solutions and Protected Areas to Improve Urban Biodiversity and Health

MacKinnon,K.; van Ham, C.; Reilly, K.; et al. Springer International Publishing (2019) CC

Biodiversity and healthy natural ecosystems, including protected areas in and around cities, provide ecosystem benefits and services that support human health, including reducing flood risk, filtering air pollutants, and providing a reliable supply of clean drinking water. These services help to red... more

Download (140)

View PDF (173)

Managing epidemics: key facts about major deadly diseases

World Health Organization (WHO) (2018) C_WHO

Epidemics of infectious diseases are occurring more often, and spreading faster and further than ever, in many different regions of the world. The background factors of this threat are biological, environmental and lifestyle changes, among others. A potentially fatal combination of newly-discovered ... more

Download (198)

View PDF (244)

Vaccines and immunization for monkeypox: Interim guidance, 16 November 2022

World Health Organization WHO (2022) C_WHO

The goal of the global outbreak response for monkeypox is to stop human-to-human transmission of monkeypox, with a priority focus on communities at high risk of exposure which may differ according to context, and to effectively use strong public health measures to prevent onward spread of the diseas... more

Download (77)

View PDF (124)

WHO manual on sugar-sweetened beverage taxation policies to promote healthy diets

World Health Organisation (WHO) (2022) C_WHO

Obesity and diet-related noncommunicable diseases (NCDs) have been steadily increasing globally, and with them, a pressing need to implement effective responses to address the contributing factors. Among the available evidence-based policy options that enable healthier choices and improved diets is ... more

Download (116)

View PDF (136)

Recommended package of interventions for HIV, viral hepatis and STI prevention, diagnosis, treatment and care for people who inject drugs: policy brief

World Health Organisation (WHO) (2023) C_WHO

HIV, viral hepatitis and STI epidemics, particularly among people who inject drugs and other key populations, continue to be fuelled by laws and policies criminalizing sex work; drug use or possession; diverse forms of gender expression and sexuality; stigma and discrimination; gender discrimination... more

Download (140)

View PDF (115)

Communicating about Vaccination-related Risks

World Health Organisation (WHO) (2023) C_WHO

This document seeks to help health communication professionals working on the topic of immunization more effectively communicate about Events Supposedly Attributed to Vaccination and Immunization (ESAVI) by building trust in National Immunization Programs, understanding risk perceptions related to v... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more